

Non-clinical studies of VRN101099, a brain permeable HER2 selective kinase inhibitor

Voronoi, Inc.



ONCOLOGY	Preclinical
Product Type	Small molecule kinase inhibitor
Indication	HER2 positive or mutant, advanced solid tumors
Target	HER2 (ERBB2) and HER mutants
MoA(Mechanism of Action)	Direct inhibition of HER2 kinase catalytic activity prevents HER2 dependent signal pathways (MAPK and PI3K) and promotes apoptosis
Competitiveness	<ul style="list-style-type: none"> • High HER2 kinase (including mutants) inhibition potency with high kinase selectivity • High margin over wild type EGFR • Brain penetration and high efficacy for brain metastasis model • Covalent inhibition with longer resident time and combinatory effects with HER2 antibody-based drugs including Enhertu • Low GSH reactivity compared to other covalent HER2 inhibitors
Development Stage	Preclinical
Route of Administration	Oral administration